PIK3CA and Hyperglycemia: The phase 3 SOLAR-1 trial of alpelisib, a PIK3CA inhibitor, demonstrated hyperglycemia as the most common adverse event occurring in 63.7% of patients, with grade 3 or 4 hyperglycemia (blood glucose level (BGL) >250 mg/dL or 13.9 mmol/L) observed in 36.6% of patients (3).